

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3464	A clinical stage company focusing on non-opioid new drug research and development for the management of pain, and is backed by top-tier investors in China.	AC3464-1	COX-2 preferential IV NSAID	Postoperative pain	Pre-registration (US)	Online
AC3477	A biopharmaceutical company in China focusing on the R&D and commercialization of novel immune cell therapies. The core team has more than 20 year-experience in CAR-T therapy area.	AC3477-3	CD19 CAR-T	Adult r/r B-ALL, B-NHL, Paedi. B-ALL	Pre-NDA (China)	SF; Online
		AC3477-1	CD19/CD22 dual targeting CAR-T	B-ALL, B-NHL	IND Filing in Q4 2022 (IIT)	SF; Online
		AC3477-2	BCMA CAR-T	MM	IND Filing in 2023 (IIT)	SF; Online
AC3242	A clinical stage biopharmaceutical company in China focused on immune regulation, discovering new targets and signalling pathways to precisely regulate the immune system, and providing the potentially best treatment options for malignant tumor, autoimmune diseases, neurodegenerative diseases and metabolic diseases.	AC3242-1	MIF inhibitor	Autoimmune diseases, oncology, neurodegenerative diseases, metabolic diseases	Phase 1 Ongoing	SF; Online
		AC3242-2	CCR8 mAb	Solid tumor, autoimmune diseases	IND Filing	SF; Online
		AC3242-3	NADase inhibitor	Metabolic diseases, neurodegenerative diseases	IND Filing	SF; Online
		AC3242-4	GPCR antagonist	Autoimmune diseases, neurodegenerative diseases	IND Filing	SF; Online
AC3150	A leading ophthalmic innovative drug R&D company in China with an international first-class ophthalmic team. It's backed by leading life sciences investors including Sequoia, Lapam, Cenova, GTJA, etc.	AC3150-1	CD11a antagonist	Xerophthalmia	Phase 3 ongoing (US)	SF; Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3495	A Chinese biopharmaceutical company focusing on treatment of cancers, autoimmune conditions, and infectious diseases.	AC3495-1	Best-in-class anti-TSLP antibody	Severe asthma, seasonal allergy, asthma, atopic dermatitis, eosinophilic esophagitis, psoriasis, IPF and cancers	Phase 1 ongoing (US)	SF; Online
		AC3495-2	Best-in-class anti-IL-1 $\beta$ antibody	Diabetic neuropathy, wound healing, pigmented villonodular synovitis, cancer	Phase 1 ongoing (US)	SF; Online
AC3440	A clinical stage company in China focusing on the field of oncology and autoimmune diseases. It has developed a novel internal pipeline of nearly 10 Best-in-Class and First-in-Class bispecific antibodies (BsAbs) and Antibody-Drug Conjugate (ADC) drugs.	AC3440-4	PD-L1/TGF- $\beta$ bispecific protein	Solid tumor	IND Filed (US, China)	SF; Online
		AC3440-5	Autoimmune ADC	IFN-I mediated chronic autoimmune diseases eg.SLE	IND Enabling	SF; Online
		AC3440-6	Autoimmune ADC	RA, IBD	IND Enabling	SF; Online
AC3044	A top 500 high-tech listed Chinese company focusing on Great Health industry.	AC3044-3	FGF21 analogues	NASH, T2DM	Phase 1a ongoing (US)	Online
AC3467	A Chinese leading developer of Ophthalmic Digital Therapeutics (DTx) and takes the top market share in China.	AC3467-1	Individual digital training	Amblyopia and exotropia	On Market (China)	Online
		AC3467-2	VR photobiological therapy	Myopia prevention and control in children	On Market (China)	Online
AC3499	A listed integrated biotechnology company in China focusing on developing innovative antibody therapies. The company was founded by medical and scientific experts and the core leadership team includes the inventors of the first PD-1 antibody drugs that were pioneered and approved in the United States and China.	AC3499-1	Recombinant humanized anti-IL-4R alpha monoclonal antibody	Atopic dermatitis, Asthma	Phase 3 ongoing (China)	SF; Online
		AC3499-2	Humanized anti-TSLP antibody	Atopic dermatitis, Asthma	Phase 1 ongoing (China)	SF; Online
		AC3499-3	Humanized anti-MASP-2 antibody	IgA nephropathy	Phase 1 ongoing (China)	SF; Online
		AC3499-4	Claudin 18.2 ADC	Advanced solid tumor	Phase 1 ongoing (China)	SF; Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3473	A R&D-driven, clinical-stage biopharmaceutical company in China dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. They have strategically designed and developed a rich pipeline of 10+ programs.	AC3473-1	CSF-1 antagonist	Solid tumors	Phase 1 ongoing (China)	SF; Online
		AC3473-2	FGFR2/3 receptor antagonist	Solid tumors	Phase 1 ongoing (China,US)	SF; Online
		AC3473-3	FGF receptor antagonist	Solid tumors	IND Enabling	SF; Online
AC3481	A Chinese company specialized in innovative nanobody new drugs, which has established laboratories and pilot field of over 1000 M2 in Shanghai International Medical Zone, including an integrated R&D platform for nanobody from discovery to IND enabling.	AC3481-1	IL-4 receptor antagonist	Asthma	Phase 1 ongoing (Australia)	SF; Online
AC3500	A clinical-stage biotech company in China, focused on immunotherapy drug research and development to treat cancer.	AC3500-1	Non-Fc-based CD3 bi-specific Abs, a bispecific antibody targeting CD3 and CD19	Lymphoma, ALL	Phase 1 ongoing (China)	SF; Online
		AC3500-2	A potent bispecific antibody that target EpCAM and CD3	Solid tumors	Phase 1 ongoing (US)	SF; Online
AC3501	A Chinese clinical-stage company mainly focused on the drug discovery & development of novel therapies for cancer treatment. The company has a world-class MedChem team.	AC3501-1	A highly potent and selective Bcl-2 inhibitor	R/R B Cell Malignances	Phase 1 Ongoing (China)	SF; Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD610C](https://jinshuju.net/f/nD610C)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3502	A start-up company in China dedicated to developing antibody-based therapeutics of cancer with innovative technologies.	AC3502-1	Trop-2 ADC	Advanced solid tumor	Phase 1 Ongoing (US)	SF; Online
AC3503	A high-tech company professionally engaged in preclinical and clinical research of new drugs for cardiovascular diseases, metabolic diseases and hepatic diseases, the innovative biological drugs of polypeptide and protein, and vaccines and biomolecule drug delivery system.	AC3503-1	Factor IIa antagonist; GP IIb IIIa antagonist	Acute coronary syndrome, percutaneous coronary intervention, ischemic stroke, hemodialysis	Phase 2 Ongoing (US) Phase 1 Ongoing (China)	SF; Online
		AC3503-2	Osteogenic growth peptide agonist, Extracellular calcium sensing receptor agonist	Secondary hyperparathyroidism, hypercalcemia of malignancy	Phase 1 ongoing (US, China)	SF; Online
AC3504	A clinical-stage biopharmaceutical company, dedicated to the development of innovative oncology drugs. The company has more than 10 differentiated innovative pipelines.	AC3504-1	505b2, a Tween 80-free injectable formulation of docetaxel	Solid tumor (breast cancer, NSCLC, prostate cancer, gastric cancer)	Pre-NDA (US)	SF; Online
AC3506	A innovation driven Chinese company, committed to developing new drugs to satisfy the patients' needs. The new drugs(NDA) include new dosage forms, new indications, and new dosing regimens. Their focusing therapeutic areas include vascular diseases, and anti-viral products development.	AC3506-1	505b2,a topical gel of Timolol Maleate, a first topical dosage form	Infantile hemangioma	Phase 2/3 Completed (China)	SF; Online
		AC3506-2	Rivaroxaban tables for oral suspension	Venous thromboembolism	NDA (China)	SF; Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3004	A leading listed biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecifics and protein engineering, delivering world-class innovative therapeutic biologics to cancer patients globally.	AC3004-1	PD-L1 antibody	Metastatic colorectal cancer	On Market	Online
AC3407	An innovative biotechnology company in China specializing in the research and development of new drugs, technology transfer and industrialization of new pharmaceutical products.	AC3407-2	EGFR-TKI	First-line EGFR positive advanced NSCLC; Second-line EGFR T790M mutation positive NSCLC	Phase 3 Ongoing	Online
AC3233	A Chinese integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, focused on research and sales of both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.	AC3233-1	BCMA/CD3	Multiple myeloma	Phase 1 Ongoing	Online
AC3466	A Chinese company focused on small molecule medicines used for cancer and immune system disorders, based on its unique TALENT technology platform.	AC3466-1	CXCR4	R/R non-Hodgkin lymphoma or multiple myeloma	Phase 1 Ongoing	Online
		AC3466-2	FGF/FGFR inhibition	Solid tumor	Phase 1 Ongoing	Online
		AC3466-3	ALK pathway	Lung cancer	Phase 1 Ongoing	Online
		AC3466-4	Eukaryotic cell cycle	Acute myeloid leukemia	IND Filling	Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD61OC](https://jinshuju.net/f/nD61OC)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3465	A biotech company in China dedicated to driving drug discovery on with AI, and bringing more value into the medical industry with diversifying pipelines, especially on undruggable and difficult-to-drug targets.	AC3465-1	S1P1 agonist	UC and MS	Pre-clinical	Online
AC3407	An innovative biotechnology company in China specializing in the research and development of new drugs, technology transfer and industrialization of new pharmaceutical products.	AC3407-1	RET inhibitor	Advanced solid malignancies with RET fusion or activating RET mutation	Phase 1 Ongoing	Online
AC3216	A biotech company dedicated to the R&D of small-molecule drugs for the treatment of diseases such as fibrosis and tumors.	AC3216-1	Mpro/3CLpro, TrxR daul-target	Pulmonary fibrosis, secondary pulmonary fibrosis caused by coronavirus	IND Filed	Online
AC3041	A science-driven biotechnology company in China dedicated to the development of next-generation immuno-oncology therapies.	AC3041-1	Anti CD47 SIRPa-Fc fusion Protein	NHL, HL and AML and MM	Phase 1b/2 Ongoing	Online
		AC3041-2	CD47xCD20 mAb-Trap	Hematology Tumor, such as B-NHL, CLL	Phase 1 Ongoing	Online
		AC3041-6	CD47xPD-L1 bi-specific antibody	Solid tumor	Pre-clinical	Online
AC3518	The company has a one-stop AI-driven drug discovery platform. Within a few months of its establishment, the company has carried out commercial cooperation with a number of listed pharmaceutical companies and has been recognized.	AC3518-1	GLP-1R agonist	Diabetes, weight loss	IND-Enabling	SF; Online

## ACCESS CHINA Biotech Forum @ JPM 2023, 1-1 Meeting Company List



[Click here to book meetings, or copy this link https://jinshuju.net/f/nD610C](https://jinshuju.net/f/nD610C)

Company Code	Company Description	AssetCode	Mode of Action	Indication	Stage	Meeting Place
AC3519	A global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing.	AC3519-2	Claudin 18 inhibitor	First-line G/GEJ cancer	Ph 2	SF; Online
		AC3519-3	BMP Antagonist	Solid tumor	IND-Enabling	SF; Online
		AC3519-4	Mannan-binding lectin serine protease-2 inhibitor	IgA nephropathy	IND-Enabling	SF; Online

### Contact us

Ms. Joanna Xu, Sr. BD Manager  
[zxu@yafocapital.com](mailto:zxu@yafocapital.com)  
[www.yafocapital.com](http://www.yafocapital.com)

### Join Us at ACCESS CHINA

Ms. Wendi Xiang, VP  
[wxiang@yafocapital.com](mailto:wxiang@yafocapital.com)  
[BioToChina.org](http://BioToChina.org)